High expression of PPARG impairs CD8+ T cell infiltration in bladder cancer and confers resistance to immunotherapies, while knockdown/inhibition of PPARG increases cytokine expression and revives immunosurveillance.33 Therefore, we speculated that the loss of PPARG in pLELC might improve immunosurveillance, leading to a good prognosis in pLELC cases. The gene discussed is PPARG; the disease is urinary bladder cancer.